Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SYRE
SYRE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SYRE News
Commodore Capital Increases Stake in Spyre Therapeutics
Feb 23 2026
Fool
Spyre Therapeutics Grants Stock Options to Employees
Feb 06 2026
Newsfilter
Spyre Therapeutics CEO Sells 15,000 Shares for $460K
Jan 11 2026
Fool
Spyre Therapeutics CEO Cameron Turtle Sells 15,000 Shares for Over $460,000
Jan 11 2026
NASDAQ.COM
Spyre Grants 42,000 Stock Options to Six Employees as Inducement Awards
Jan 08 2026
Globenewswire
Biotech Sector Sustains After-Hours Trading Gains
Dec 18 2025
NASDAQ.COM
Spyre Therapeutics Grants 20,300 Stock Options to Employees as Inducement Awards
Dec 05 2025
Globenewswire
Spyre Grants 20,300 Stock Options to Employees Under Equity Inducement Plan
Dec 05 2025
Newsfilter
Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday
Dec 01 2025
Benzinga
Top Analysts Recommend 3 Best Stocks to Purchase as of December 1, 2025
Dec 01 2025
TipRanks
Spyre Therapeutics (SYRE) Reports Encouraging Outcomes from Phase 1 Trial of SPY003
Nov 17 2025
Yahoo Finance
Analyst Starts Coverage on United Therapeutics with Optimism; Check Out the Top 5 Initiations for Friday
Sep 26 2025
Benzinga
BTIG Affirms Buy Rating for Spyre Therapeutics, Keeps $70 Price Target Intact
Sep 16 2025
Benzinga
Spyre Therapeutics Administers Initial Dose to Patient in Groundbreaking Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Investigated for Rheumatic Diseases
Sep 15 2025
Newsfilter
Spyre Therapeutics Reveals Inducement Award Grants
Sep 05 2025
Newsfilter
The Math Shows SCHA Can Go To $31
Aug 07 2025
NASDAQ.COM
Show More News
